Terra Alpha Investments LLC Purchases 334 Shares of Agilent Technologies, Inc. (NYSE:A)

Terra Alpha Investments LLC lifted its position in shares of Agilent Technologies, Inc. (NYSE:A) by 1.4% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 24,229 shares of the medical research company’s stock after purchasing an additional 334 shares during the period. Agilent Technologies accounts for about 3.1% of Terra Alpha Investments LLC’s holdings, making the stock its 16th biggest position. Terra Alpha Investments LLC’s holdings in Agilent Technologies were worth $2,834,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Norges Bank purchased a new position in Agilent Technologies in the fourth quarter worth $456,963,000. Madison Investment Advisors LLC bought a new stake in shares of Agilent Technologies during the 4th quarter worth $94,051,000. GAMMA Investing LLC boosted its holdings in shares of Agilent Technologies by 15,648.1% in the 1st quarter. GAMMA Investing LLC now owns 627,247 shares of the medical research company’s stock worth $73,375,000 after buying an additional 623,264 shares during the last quarter. Two Sigma Investments LP boosted its holdings in shares of Agilent Technologies by 345.9% in the 4th quarter. Two Sigma Investments LP now owns 769,897 shares of the medical research company’s stock worth $103,428,000 after buying an additional 597,249 shares during the last quarter. Finally, Iron Triangle Partners LP bought a new position in Agilent Technologies during the fourth quarter valued at about $80,110,000.

Agilent Technologies Stock Up 0.8%

A stock opened at $116.77 on Tuesday. The stock has a 50-day simple moving average of $108.11 and a two-hundred day simple moving average of $125.77. Agilent Technologies, Inc. has a twelve month low of $96.43 and a twelve month high of $153.84. The firm has a market capitalization of $33.17 billion, a PE ratio of 28.83, a PEG ratio of 3.52 and a beta of 1.23. The company has a quick ratio of 1.60, a current ratio of 2.09 and a debt-to-equity ratio of 0.55.

Agilent Technologies (NYSE:A) last released its quarterly earnings results on Wednesday, May 28th. The medical research company reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.26 by $0.05. The firm had revenue of $1.67 billion for the quarter, compared to analysts’ expectations of $1.63 billion. Agilent Technologies had a net margin of 17.59% and a return on equity of 25.92%. The business’s quarterly revenue was up 6.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.22 earnings per share. On average, equities analysts predict that Agilent Technologies, Inc. will post 5.58 EPS for the current fiscal year.

Agilent Technologies Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, July 23rd. Shareholders of record on Tuesday, July 1st will be issued a $0.248 dividend. The ex-dividend date is Tuesday, July 1st. This represents a $0.99 annualized dividend and a dividend yield of 0.85%. Agilent Technologies’s payout ratio is currently 24.44%.

Insider Transactions at Agilent Technologies

In other Agilent Technologies news, Director Daniel K. Podolsky sold 1,819 shares of Agilent Technologies stock in a transaction dated Monday, March 31st. The stock was sold at an average price of $116.46, for a total transaction of $211,840.74. Following the completion of the sale, the director now owns 35,737 shares of the company’s stock, valued at $4,161,931.02. The trade was a 4.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Rodney Gonsalves sold 1,908 shares of the stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $121.98, for a total value of $232,737.84. Following the transaction, the vice president now owns 21,786 shares in the company, valued at $2,657,456.28. This trade represents a 8.05% decrease in their ownership of the stock. The disclosure for this sale can be found here.

Analyst Upgrades and Downgrades

A has been the topic of several research reports. Barclays lowered their price objective on shares of Agilent Technologies from $138.00 to $115.00 and set an “equal weight” rating on the stock in a research report on Thursday, April 10th. Wells Fargo & Company lowered their price target on shares of Agilent Technologies from $155.00 to $135.00 and set an “overweight” rating on the stock in a report on Thursday, April 17th. Leerink Partners raised their target price on Agilent Technologies to $135.00 and gave the stock a “buy” rating in a research report on Friday, May 30th. TD Cowen increased their price target on Agilent Technologies to $150.00 and gave the stock a “buy” rating in a research note on Thursday, May 29th. Finally, Robert W. Baird decreased their price objective on Agilent Technologies from $159.00 to $140.00 and set an “outperform” rating for the company in a report on Thursday, May 22nd. Seven research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat, Agilent Technologies has an average rating of “Moderate Buy” and an average target price of $140.15.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.